MeSH term
Frequency | Condition_Probility | Humans | 90 | 0.0 |
Adult | 20 | 0.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Female | 33 | 0.0 |
Gene Expression | 4 | 0.0 |
Middle Aged | 15 | 0.0 |
Research Support, Non-U.S. Gov't | 56 | 0.0 |
Thrombopoietin/*metabolism | 6 | 22.0 |
Amino Acid Motifs | 2 | 0.0 |
Amino Acid Sequence | 12 | 0.0 |
Cell Division | 8 | 0.0 |
Cell Line | 28 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
*Neoplasm Proteins | 35 | 4.0 |
Phosphorylation | 12 | 0.0 |
*Receptors, Cytokine | 29 | 21.0 |
Research Support, U.S. Gov't, P.H.S. | 31 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Thrombopoietin/pharmacology | 4 | 7.0 |
Tyrosine/metabolism | 3 | 0.0 |
Animals | 62 | 0.0 |
Immunization | 6 | 1.0 |
Mice | 49 | 0.0 |
Drug Synergism | 5 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Thrombopoietin/*pharmacology | 11 | 11.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Cells, Cultured | 12 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Thrombopoietin/metabolism/pharmacology | 2 | 100.0 |
Adjuvants, Immunologic/*pharmacology | 7 | 4.0 |
Immune Sera/pharmacology | 2 | 2.0 |
Lipid A/*analogs & derivatives/*pharmacology | 2 | 40.0 |
Mitogen-Activated Protein Kinases/metabolism | 6 | 0.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Pregnancy | 3 | 0.0 |
Rats | 2 | 0.0 |
Safety | 2 | 1.0 |
Tyrosine | 2 | 1.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Cell Division/drug effects | 10 | 0.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 2 | 3.0 |
*Milk Proteins | 6 | 1.0 |
Protein Transport | 2 | 0.0 |
Signal Transduction | 11 | 0.0 |
Immunity, Cellular/immunology | 2 | 3.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Bone Marrow Cells/metabolism | 2 | 2.0 |
Cytokines/biosynthesis | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 9 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Genetic Vectors | 5 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Mice, Inbred BALB C | 10 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Receptors, Cytokine/*metabolism | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Retroviridae/genetics | 3 | 0.0 |
*Signal Transduction | 4 | 0.0 |
Time Factors | 6 | 0.0 |
Trans-Activators/metabolism | 8 | 0.0 |
src Homology Domains | 2 | 0.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/genetics/metabolism | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Transfection | 10 | 0.0 |
Adjuvants, Immunologic/adverse effects/*therapeutic use | 2 | 25.0 |
Comparative Study | 16 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Immunoglobulin G/blood | 3 | 1.0 |
Male | 22 | 0.0 |
Megakaryocytes/*physiology | 2 | 11.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Administration, Intranasal | 2 | 2.0 |
Antibody Specificity | 4 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
HIV-1/*immunology | 4 | 0.0 |
Neutralization Tests | 3 | 0.0 |
Aged | 8 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Flow Cytometry | 5 | 0.0 |
Protein Binding | 5 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Mutation | 5 | 0.0 |
Cell Lineage | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology | 2 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 5 | 0.0 |
Proto-Oncogene Proteins/*chemistry/genetics/*metabolism | 2 | 10.0 |
Aged, 80 and over | 3 | 0.0 |
Biological Markers/blood | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Tumor Cells, Cultured | 10 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Leukemia Virus, Murine/genetics | 2 | 14.0 |
Ligands | 4 | 0.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 5 | 1.0 |
Base Sequence | 9 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Cell Division/genetics | 4 | 1.0 |
Kinetics | 5 | 0.0 |
Point Mutation | 3 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Immunoblotting | 3 | 0.0 |
Thrombopoietin/*pharmacology/physiology | 2 | 66.0 |
Megakaryocytes/metabolism | 4 | 10.0 |
Cell Survival | 2 | 0.0 |
Cytokines/metabolism | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Bacterial Outer Membrane Proteins/immunology | 2 | 10.0 |
Bacterial Vaccines/*immunology | 2 | 8.0 |
Follow-Up Studies | 3 | 0.0 |
Lithotripsy/*instrumentation | 2 | 66.0 |
Treatment Outcome | 3 | 0.0 |
Hamsters | 2 | 0.0 |
Ploidies | 3 | 1.0 |
Sequence Deletion | 2 | 0.0 |
Adjuvants, Immunologic/*administration & dosage | 6 | 19.0 |
Antibody Affinity | 2 | 1.0 |
Disease Models, Animal | 3 | 0.0 |
Squalene/administration & dosage | 2 | 100.0 |
Mice, Inbred DBA | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Cell Differentiation | 5 | 0.0 |
Megakaryocytes/*metabolism | 3 | 9.0 |
Transduction, Genetic | 2 | 0.0 |
Hematopoiesis/genetics | 2 | 5.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Stem Cells/metabolism | 2 | 2.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Child | 8 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/analysis | 2 | 8.0 |
Aerosols | 2 | 2.0 |
Anthrax/*prevention & control | 2 | 100.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Hepatitis B Surface Antigens/immunology | 2 | 8.0 |
Mice, Inbred ICR | 2 | 0.0 |
HIV Antibodies/biosynthesis | 2 | 10.0 |
Hypersensitivity, Delayed | 2 | 3.0 |
Lipid A/administration & dosage/*analogs & derivatives | 3 | 100.0 |
Lipid A/*analogs & derivatives/pharmacology | 3 | 15.0 |
Stimulation, Chemical | 2 | 0.0 |
Lipid A/*analogs & derivatives/immunology | 3 | 100.0 |
T-Lymphocytes, Cytotoxic/immunology | 3 | 0.0 |
Chronic Disease | 2 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Biological Markers | 4 | 0.0 |
Megakaryocytes/cytology/drug effects | 2 | 15.0 |
Solubility | 2 | 0.0 |
*Adjuvants, Immunologic | 5 | 16.0 |
Liposomes | 5 | 1.0 |
Drug Therapy, Combination | 4 | 0.0 |
English Abstract | 8 | 0.0 |
Granisetron/*administration & dosage | 3 | 100.0 |
Methylprednisolone/*administration & dosage | 4 | 21.0 |
Adolescent | 7 | 0.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Drug Carriers | 2 | 1.0 |
Emulsions | 3 | 4.0 |
Microspheres | 2 | 1.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Guinea Pigs | 3 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Proto-Oncogene Proteins/chemistry/genetics/*metabolism | 2 | 3.0 |
Receptors, Cytokine/chemistry/genetics/*metabolism | 2 | 33.0 |
Malaria, Falciparum/prevention & control | 2 | 100.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
Antibody Formation/immunology | 2 | 4.0 |
Vaccines, Synthetic/immunology | 3 | 9.0 |
Lipid A/*immunology | 2 | 33.0 |
Evaluation Studies | 3 | 0.0 |
Allergens/*immunology | 2 | 2.0 |
Adjuvants, Immunologic/administration & dosage | 2 | 11.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Vaccines/*administration & dosage | 2 | 40.0 |
